We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Paul Hudson needs to convince investors that pharma group’s new blockbuster drugs will be successful
Paul Hudson is meeting investors to explain multibillion-euro push to get drug candidates to market
Evobrutinib would have more than compensated for falling sales from German group’s existing medicines
Evobrutinib failed to reduce relapse rates compared with teriflunomide, produced by rival Sanofi
New approach is driving a wave of mergers and acquisitions in the healthcare industry
BMA announces nine days of action as pay negotiations with government break down
Wuxi Biologics is likely to miss its original sales target for the year by about $400mn
Pharma group behind blockbuster drug wants to supersize its market impact
Members of the company’s founding family fight to uphold protections from $6bn opioid bankruptcy settlement in closely watched case
The Swiss pharma group needs to settle investor jitters with its latest acquisition
Swiss pharmaceutical group is under pressure to strengthen its pipeline of medicines
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Steady shift towards outsourcing hip, knee and eye treatment expected to expand to other procedures despite concerns
Group plans to refocus on 30 core brands
Decision is setback for US drugmaker looking to increase sales after pandemic
Any combination would likely encounter tough antitrust scrutiny
Expect earnings estimates to weaken following the FDA’s safety communication
Key drugs are due to lose exclusivity in the important US market in 2027
Clampdown on visas will not solve workforce crisis in underfunded sector, say unions and employers
Cancer Research UK report says UK government must invest in staffing and funding for research
Innovative models can drive funding for research on neglected, less survivable diseases
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
Demand is soaring thanks to the NHS crisis, but providers are up against inflation and fierce competition for doctors
Bill Anderson says group is generating a series of promising new drugs after R&D strategy change
Health body’s concern reflects heightened vigilance over signs of disease outbreaks since Covid pandemic
International Edition
